**Core Concept**
d-Tubocurarine is a non-depolarizing neuromuscular blocking agent that competes with acetylcholine for receptors at the neuromuscular junction. This results in muscle paralysis, making it useful in surgical procedures.

**Why the Correct Answer is Right**
d-Tubocurarine acts by competitively inhibiting the nicotinic acetylcholine receptors (nAChRs) at the neuromuscular junction. It binds to the same receptors as acetylcholine, preventing acetylcholine from binding and triggering muscle contraction. This leads to a reduction in muscle contraction force and eventually to muscle paralysis.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is not a correct description of d-Tubocurarine's mechanism of action.
**Option B:** d-Tubocurarine does not act by inhibiting acetylcholinesterase, which is the enzyme responsible for breaking down acetylcholine.
**Option C:** d-Tubocurarine does not act by stimulating the nicotinic receptors; rather, it competitively inhibits them.

**Clinical Pearl / High-Yield Fact**
Non-depolarizing neuromuscular blocking agents like d-Tubocurarine can be reversed with anticholinesterases like neostigmine, which increases acetylcholine levels and helps restore muscle function.

**Correct Answer: C. competitively inhibiting the nicotinic acetylcholine receptors (nAChRs) at the neuromuscular junction.**